# Cannabinoids for Children: Evidence-Based Clinical Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoids-pediatric-medical-conditions-clinical-review/ > **Published:** 2026-03-13T13:15:50-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:58:55-04:00 > **Clinical Summary:** Explore cannabinoids pediatric medical conditions with evidence-based clinical review highlighting safety and efficacy in children. --- #### Clinical Takeaway Cannabinoids have been studied across a range of pediatric medical conditions, with the current evidence base drawing from over 270 studies including clinical trials and observational reports. The data suggest potential benefits in select conditions, but the overall quality and consistency of evidence remains variable. Clinicians should weigh reported benefits against safety considerations on a case-by-case basis when evaluating cannabinoid use in patients under 18. ### #2 Cannabinoids for Medical Purposes in Children: A Living Systematic Review. **Citation:** Chhabra Manik et al. *Cannabinoids for Medical Purposes in Children: A Living Systematic Review.* Acta paediatrica (Oslo, Norway: 1992). 2025. PMID: 40437694. **Study type:** Journal Article, Systematic Review  |  **Topic area:** Autism  |  **CED Score:** 13 Design: 5 Journal: 0 N: 2 Recency: 2 Pop: 3 Human: 1 Risk: 0 Why This Matters This living systematic review establishes an evidence foundation for cannabinoid use in pediatric populations by systematically synthesizing safety and efficacy data across multiple databases, addressing a critical knowledge gap given the expanding clinical interest in cannabinoids for childhood conditions. The continuous update mechanism ensures clinicians have access to evolving evidence as new trials emerge, enabling more informed decision-making regarding cannabinoid administration in children where regulatory frameworks and clinical guidance remain limited. **Methodological Considerations:** - Small sample — underpowered for subgroup analysis **Abstract:** AIM: We developed a living systematic review (LSR) that will continuously map the safety and reported benefit data related to cannabinoid use for medical purposes in children. METHODS: MEDLINE, Embase, PsycInfo, and the Cochrane Library were searched from inception to April 2023. Studies involving at least one child  20% studies) in studies enrolling children were somnolence, diarrhoea, vomiting, and decreased appetite. CONCLUSION: These findings will continue to be updated to inform practice and reveal knowledge gaps for future research. Clinical Perspective This living systematic review represents a necessary effort to consolidate evidence on pediatric cannabinoid use, yet several important limitations merit consideration before applying findings to clinical practice. The heterogeneity of study designs, patient populations, and cannabinoid formulations makes direct comparison difficult, and many included studies likely lack the methodological rigor of randomized controlled trials, particularly regarding long-term safety outcomes in developing brains. Publication bias toward positive findings and the evolving regulatory landscape surrounding [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) means that evidence quality varies considerably across therapeutic indications. Clinicians considering [cannabinoid therapy](https://cedclinic.com/unknown-cannabinoid-receptor-brain-damage-relief/) in pediatric patients should focus on conditions with the strongest evidence base (such as treatment-resistant epilepsy), maintain realistic expectations about effect sizes, and engage in shared decision-making that acknowledges both potential benefits and the genuine gaps in our understanding of neurodevelopmental safety in children and adolescents.  |   |  Further Reading Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) Cannabis Policy Wire[Schedules of Controlled Substances: Temporary Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I](https://cedclinic.com/dea-temporary-placement-schedule-i-n-desethyl-isotonitazene/) CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40437694/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336964/)[DOI ↗](https://doi.org/10.1111/apa.70140) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoids in Pediatric Medicine: Evidence-Based Care and Emerging Research](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) An in-depth look at cannabinoids in pediatric medicine, focusing on evidence-based care and the latest research developments. [Read More](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) [Cannabinoids for Pediatric Medicine: Clinical Evidence Review](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) Comprehensive clinical evidence review on the use of cannabinoids in pediatric medicine, highlighting safety and therapeutic potential. [Explore Article](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) [Medical Cannabis in Pediatrics: Evidence-Based Endocannabinoid Research and Clinical Trials](https://cedclinic.com/cannabinoids-pediatric-medicine-evidence-clinical-trials/) A detailed review of [medical cannabis research](https://cedclinic.com/cannabis-varieties-differentiation-cannabinomics/) and clinical trials focused on pediatric populations and [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) implications. [Discover Insights](https://cedclinic.com/cannabinoids-pediatric-medicine-evidence-clinical-trials/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoids%20for%20Children%3A%20Evidence-Based%20Clinical%20Review&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-pediatric-medical-conditions-clinical-review%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoids-pediatric-medical-conditions-clinical-review%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoids%20for%20Children%3A%20Evidence-Based%20Clinical%20Review%20https%3A%2F%2Fcedclinic.com%2Fcannabinoids-pediatric-medical-conditions-clinical-review%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).